SG11201901993SA - Use of recombinant lymphocyte activation gene-3 - Google Patents

Use of recombinant lymphocyte activation gene-3

Info

Publication number
SG11201901993SA
SG11201901993SA SG11201901993SA SG11201901993SA SG11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA SG 11201901993S A SG11201901993S A SG 11201901993SA
Authority
SG
Singapore
Prior art keywords
international
lag3
risk
lymphocyte activation
recombinant
Prior art date
Application number
SG11201901993SA
Other languages
English (en)
Inventor
Oquendo Annabelle Rodriguez
Original Assignee
Oquendo Annabelle Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oquendo Annabelle Rodriguez filed Critical Oquendo Annabelle Rodriguez
Publication of SG11201901993SA publication Critical patent/SG11201901993SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
SG11201901993SA 2015-09-16 2017-09-12 Use of recombinant lymphocyte activation gene-3 SG11201901993SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219429P 2015-09-16 2015-09-16
US15/262,618 US10265379B2 (en) 2015-09-16 2016-09-12 Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
PCT/US2017/051210 WO2018049410A1 (fr) 2015-09-16 2017-09-12 Utilisation d'un gène 3 recombiné d'activation des lymphocytes en tant qu'agent thérapeutique d'accompagnement destiné à des patients à risque pour une maladie cardiovasculaire et d'autres maladies inflammatoires chroniques

Publications (1)

Publication Number Publication Date
SG11201901993SA true SG11201901993SA (en) 2019-04-29

Family

ID=60157173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901993SA SG11201901993SA (en) 2015-09-16 2017-09-12 Use of recombinant lymphocyte activation gene-3

Country Status (12)

Country Link
US (2) US10265379B2 (fr)
EP (1) EP3510410A4 (fr)
JP (1) JP2019534318A (fr)
KR (2) KR20190049844A (fr)
CN (1) CN109716139A (fr)
AU (2) AU2017322742A1 (fr)
BR (1) BR112019004703A2 (fr)
CA (1) CA3036090A1 (fr)
IL (1) IL265258A (fr)
MX (1) MX2019002821A (fr)
SG (1) SG11201901993SA (fr)
WO (1) WO2018049410A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265379B2 (en) * 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2018165574A1 (fr) * 2017-03-10 2018-09-13 The Regents Of The University Of California Procédé de diagnostic du risque de maladie inflammatoire par profilage de glycane
WO2022113727A1 (fr) * 2020-11-27 2022-06-02 オートリブ ディベロップメント エービー Dispositif coussin de sécurité gonflable de protection de piéton

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (fr) 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
EP2044949A1 (fr) * 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
US9995759B2 (en) * 2012-12-06 2018-06-12 Annabelle Rodriguez Oquendo Use of lymphocyte activation gene 3 (LAG-3) expression profiling as a biomarker for assessing inflammasomes, chronic inflammatory diseases and dysfunctional HDL
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US10265379B2 (en) * 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases

Also Published As

Publication number Publication date
EP3510410A4 (fr) 2020-03-25
IL265258A (en) 2019-05-30
BR112019004703A2 (pt) 2019-05-28
KR20210043011A (ko) 2021-04-20
JP2019534318A (ja) 2019-11-28
EP3510410A1 (fr) 2019-07-17
US10265379B2 (en) 2019-04-23
CA3036090A1 (fr) 2018-03-15
WO2018049410A1 (fr) 2018-03-15
AU2023282264A1 (en) 2024-01-18
US20190365855A1 (en) 2019-12-05
US10751388B2 (en) 2020-08-25
KR20190049844A (ko) 2019-05-09
US20170312338A1 (en) 2017-11-02
CN109716139A (zh) 2019-05-03
MX2019002821A (es) 2019-09-19
AU2017322742A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201908090VA (en) Biomonitoring devices, methods, and systems for use in a bathroom setting
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201909344SA (en) Anti-lag3 antibodies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201903946SA (en) Devices and methods for slurry generation
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804309PA (en) Antibody molecules to april and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201806282XA (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201900509YA (en) Simultaneous capturing of overlay signals from multiple targets
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201901993SA (en) Use of recombinant lymphocyte activation gene-3